Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

315
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
315
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

244
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
244
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

353
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
353
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

207
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
207
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

278
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
278
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

212
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
212

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cross-definition GWAS of IBS in 2.8 million individuals reveals cardiometabolic and triglyceride-linked mechanisms.

Gut·2026
Same author

A predisposing effect of HLA class II genes in celiac disease by skewing the naive CD4<sup>+</sup> T cell receptor repertoire.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

The effect of prior proton pump inhibitor use on gastric cancer survival: A population-based cohort study in the five Nordic countries.

The American journal of gastroenterology·2026
Same author

Learning and deskilling effects of artificial intelligence in colonoscopy among endoscopists with different levels of experience: a pragmatic, prospective trial.

Endoscopy·2026
Same author

Long-term changes in disease extent and severity in ulcerative colitis: a population-based cohort from the Norwegian HUNT study, (2002-2024).

Scandinavian journal of gastroenterology·2026
Same author

Twenty-Three-Year Benefits of Sigmoidoscopy Screening for Colorectal Cancer : A Randomized Trial.

Annals of internal medicine·2026

Related Experiment Video

Updated: Sep 19, 2025

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.3K

Fecal Microbiota Transplantation Versus Vancomycin for Primary Clostridioides difficile Infection : A Randomized

Frederik Emil Juul1, Michael Bretthauer2, Peter H Johnsen3

  • 1Clinical Effectiveness Research Group, Oslo University Hospital, Oslo, Norway; Clinical Effectiveness Research Group, University of Oslo, Oslo, Norway; and Vestre Viken Bærum Hospital, Gjettum, Norway (F.E.J.).

Annals of Internal Medicine
|June 16, 2025
PubMed
Summary

Fecal microbiota transplantation (FMT) shows promise as a first-line treatment for primary Clostridioides difficile infection (CDI), demonstrating comparable efficacy and safety to standard vancomycin therapy. This study suggests FMT could be a viable alternative for initial CDI management.

More Related Videos

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

9.1K
Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

3.0K

Related Experiment Videos

Last Updated: Sep 19, 2025

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.3K
A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

9.1K
Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

3.0K

Area of Science:

  • Gastroenterology
  • Infectious Diseases
  • Microbiome Research

Background:

  • Fecal microbiota transplantation (FMT) is a recommended treatment for recurrent Clostridioides difficile infection (CDI).
  • The efficacy and safety of FMT for primary (initial) CDI are not well-established.
  • This study aimed to clarify the role of FMT in treating patients with their first episode of CDI.

Purpose of the Study:

  • To investigate the efficacy and safety of FMT as a first-line treatment for primary Clostridioides difficile infection (CDI).
  • To compare FMT without antibiotic pretreatment to standard oral vancomycin therapy for primary CDI.
  • To determine if FMT is noninferior to vancomycin for achieving clinical cure and preventing recurrence in primary CDI.

Main Methods:

  • A randomized, open-label, multicenter, noninferiority trial was conducted involving adult patients diagnosed with primary CDI.
  • Participants were assigned to receive either FMT without antibiotic pretreatment or oral vancomycin for 10 days.
  • The primary endpoint was clinical cure, defined as firm stools or fewer than three bowel movements daily at day 14, with no disease recurrence within 60 days, using only the assigned treatment.

Main Results:

  • Of 104 randomized patients, 100 were analyzed. Clinical cure and no recurrence within 60 days without additional treatment occurred in 66.7% of the FMT group versus 61.2% of the vancomycin group.
  • FMT was found to be noninferior to vancomycin for primary CDI treatment (P for noninferiority < 0.001).
  • When considering treatment with or without additional therapies, FMT showed a higher cure rate (78.4%) compared to vancomycin (61.2%), with no significant difference in adverse events between the groups.

Conclusions:

  • Fecal microbiota transplantation (FMT) may be considered as a first-line therapy for patients with primary Clostridioides difficile infection (CDI).
  • The study results support the use of FMT as an effective and safe alternative to vancomycin for initial CDI treatment.
  • Further research may explore optimal protocols and long-term outcomes of FMT in primary CDI.